Latest News & Features
Europe
A new referral to the CJEU should shed light on the extent of the so-called Bolar exemption in Europe, says Bernd Allekotte. 28 February 2014
Americas
Apexigen uses antibodies derived from rabbits to develop therapies for diseases that are difficult to treat. LSIPR found out how it protects its novel technologies. 28 February 2014
Europe
Recent CJEU decisions on SPCs have brought little clarity to the meaning of ‘product’, and a recent Advocate General opinion in Bayer CropScience AG threatens to muddy the waters even further, says Paul England. 28 February 2014
Asia
Bayer has announced that it plans to acquire Dihon Pharmaceutical Group, a Chinese company that makes over-the-counter (OTC) and herbal traditional Chinese medicine (TCM) products. 27 February 2014
Americas
The US District Court for the District of Maryland has ruled that Taiwanese company TWi Pharmaceuticals’ generic version of Par Pharmaceuticals’ Megace ES drug does not infringe US patent 7,101,576. 25 February 2014
Americas
Bayer will acquire Norwegian pharmaceutical company Algeta for €2.1 billion ($2.9 million), it announced on Monday. 24 February 2014
Americas
Actavis has announced another expansion with the $25 billion acquisition of US pharmaceutical company Forest Laboratories. 21 February 2014
article
The rise of so-called personalised medicine presents new challenges and opportunities for drugs companies, says Robert Andrews. 19 February 2014
Asia
The Indian Supreme Court has failed to provide the clarity which is craved by practitioners in its latest pronouncement on the controversial Section 3(d), says Jitesh Kumar. 19 February 2014
Big Pharma
Common themes, in particular in the context of second medical use claims and dosage regimes, are on the radar of the UK courts, as Jennifer Antcliff and Dennis Waller report. 19 February 2014